Core Viewpoint - The announcement details the expected daily related transactions for Jiangxi Tianxin Pharmaceutical Co., Ltd. in 2026, emphasizing that these transactions will not affect the company's independence or financial stability [2][32]. Group 1: Daily Related Transactions Overview - The board of directors approved the expected daily related transactions for 2026 on January 26, 2026, with a voting result of 6 in favor and 0 against [2][4]. - The expected total amount for daily related transactions in 2026 is capped at 68.4725 million RMB [8]. - The transactions include services such as processing vitamin E powder and providing meeting services, as well as leasing properties for employee accommodation [8][31]. Group 2: Impact and Compliance - The independent directors reviewed the proposal on January 22, 2026, and unanimously agreed that the transactions align with the company's business development and do not harm the interests of shareholders, particularly minority shareholders [4][32]. - The company asserts that these transactions are normal business activities and are conducted at market prices, ensuring fairness and compliance with relevant laws and regulations [31][32]. Group 3: Related Parties - The related parties involved include Zhejiang Xinweishi Biotechnology Co., Ltd., Qi Shan Tiancheng Vinegar Industry Co., Ltd., and Shanghai Nuirui Biotechnology Co., Ltd., all of which are under the indirect control of the company's actual controller, Xu Jiangnan [10][11][13][14]. - The announcement provides detailed information about the related parties, including their registration details, capital structure, and business scope [10][11][13][14].

Group 1 - The company announced the extension of the expected operational dates for several investment projects without changing the implementation subject, location, or investment scale [2] - The projects affected include the annual production of 6,000 tons of Vitamin A powder, 20,000 tons of Vitamin E powder, 5,000 tons of Vitamin B6, 200 tons of Biotin, and 10,000 tons of L-Alanine (fermentation method) along with a biomanufacturing pilot base project [2]

Group 1 - The company Zhejiang Huayuan Biopharmaceutical Co., Ltd. has issued convertible bonds to unspecified investors, with a total amount of RMB 1.2 billion [2][3] - The bonds have a maturity of 6 years, with an annual interest rate that increases from 0.3% in the first year to 2.5% in the sixth year [4][5] - The initial conversion price for the bonds is set at RMB 15.19 per share, subject to adjustments based on various corporate actions [5][6] Group 2 - The funds raised from the bond issuance will be used for projects including the production of 6,000 tons of Vitamin A powder and 20,000 tons of Vitamin E powder, with a total investment of RMB 134.446 million [12][13] - The company plans to adjust the use of raised funds, reallocating some towards a new project for producing 1 billion solid dosage forms and 8 million injections, with a total investment of RMB 19.11 million [22][23] - The project aims to enhance the company's R&D and production capabilities, addressing the growing demand for high-quality pharmaceuticals in various therapeutic areas [23][24] Group 3 - The company has faced increased competition in the generic drug market, prompting a strategic shift in its investment focus [21][24] - The new project is expected to improve the company's production efficiency and meet international quality standards, ultimately benefiting patients [23][25] - The project is aligned with national policies promoting the development of innovative pharmaceuticals and aims to strengthen the company's market position [26][27]